Source comparison
Top MK-677 Studies: Research Comparison
Chapman 1997 Healthy young adults (n=32) Single dose 10mg, 25mg, 50mg GH secretion profile 25mg oral dose produced GH levels equivalent to 0.03mg/kg subcutaneous rhGH; pulsatile secretion preserved Established proof-of-concept that oral ghrelin agonism could r
This comparison does not assign a generated winner or score.
- Chapman 1997
- Healthy young adults (n=32)
- Single dose
- 10mg, 25mg, 50mg
- GH secretion profile
- 25mg oral dose produced GH levels equivalent to 0.03mg/kg subcutaneous rhGH; pulsatile secretion preserved
- Established proof-of-concept that oral ghrelin agonism could replicate exogenous GH effects without suppressing endogenous pulsatility. This is the study all subsequent research references
- Nass 2004
- Elderly hip fracture patients (n=65)
- 12 months
- 25mg daily
- Femoral neck BMD
- Primary endpoint not met (p=0.09); lean mass +1.1kg, gait speed improved, falls reduced 40%
- Classified as a failed trial but produced the most cited functional outcome data in the field. The BMD endpoint was likely underpowered and timed wrong for bone remodeling cycles
- Murphy 2006
- Healthy elderly (n=24)
- 24 months
- Body composition, BMD
- Lean mass +2.1kg at 24mo, BMD declined year 1 then rebounded +2.3% by month 24
- Longest published trial; demonstrated that bone effects follow remodeling physiology and require multi-year observation. Short trials systematically underestimate skeletal benefits
- Copinschi 1997
- Healthy young men (n=8)
- 7 days
- 25mg nightly
- Sleep architecture (polysomnography)
- Stage 4 SWS duration increased 50%, REM percentage increased, no tolerance observed
- Small n but rigorous EEG measurement. This is the only trial that objectively quantified sleep changes rather than relying on self-report
- Svensson 1998
- GH-deficient adults (n=24)
- 4 weeks
- 10mg, 25mg daily
- IGF-1 elevation, safety
- IGF-1 increased 39–89% dose-dependently; fasting glucose elevated 6–9 mg/dL transiently
- Documented the insulin resistance concern that shaped all subsequent trial designs; glucose elevation was transient and didn't progress to dysglycemia in extended follow-up